TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03411-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Hai-Yan Ni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, No. 81, Meishan Road, Hefei, 230032, Anhui, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, RNA, Long Noncoding, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Translocation, Genetic. Die Arbeit nennt 45 Literaturangaben. Gefördert von: the Graduate Research and Practice Innovation Project of Anhui Medical University, the National Natural Science Foundation of China, the Research Fund of Anhui Institute of Translational Medicine.
Abstract (Originalsprache)
T(6;11) translocation renal cell carcinoma (RCC) is a distinct renal tumor distinguished by the generation of Alpha-TFEB fusion gene. TFEB is highly expressed in this subtype and may drive its progression. However, its underlying mechanism remains incompletely elucidated. The current study is intended to explore whether TFEB promotes the progression of t(6;11) translocation RCC by regulating long intergenic non-protein coding RNA (LINC)00612 expression. HK-2-TFEB and Caki-2-TFEB were stably transfected cell lines with Alpha-TFEB fusion gene, which were successfully established in our research group's previous work. Western blotting was carried out to assess TFEB protein expression, and qRT-PCR was employed to measure LINC00612, microRNA (miR)-31-5p and CTNNB1 expression levels. Bioinformatics analysis, dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays were employed to validate the interactions between TFEB and LINC00612, LINC00612 and miR-31-5p, as well as miR-31-5p and CTNNB1. Wound healing, CCK-8 and invasion assays were used to verify the effects exerted by LINC00612 downregulation and upregulation, as well as CTNNB1 downregulation on the biological functionalities of cells. Experiments carried out in vivo were designed to assess the effects of TFEB, LINC00612 and miR-31-5p on tumor growth. Western blotting showed high expression of TFEB in HK-2-TFEB and Caki-2-TFEB cells compared to their respective control cells. qRT-PCR revealed enhanced expression of LINC00612, decreased miR-31-5p expression and increased expression of CTNNB1 in HK-2-TFEB and Caki-2-TFEB cells. Dual-luciferase reporter and ChIP experiments confirmed that TFEB specifically bound to the promoter of LINC00612. LINC00612 overexpression in HK-2 cells enhanced cell proliferative capacity, migratory activity, and invasive potential, while its knockdown in HK-2-TFEB cells suppressed these cellular processes. LINC00612 was shown to have targeted binding to miR-31-5p, and miR-31-5p was verified to target CTNNB1. In vivo experiments demonstrated that either TFEB or LINC00612 overexpression promoted tumor growth, whereas overexpression of miR-31-5p inhibited tumor growth. Our findings suggested that overexpression of TFEB upregulated LINC00612 expression and LINC00612 competitively inhibited miR-31-5p, which directly targeted the downstream gene CTNNB1, ultimately promoting tumor progression. TFEB/LINC00612/miR-31-5p axis may be a new molecular therapeutic target for t(6;11) translocation RCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, No. 81, Meishan Road, Hefei, 230032, Anhui, China.
- Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Hefei, 230601, Anhui, China.
- Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, No. 81, Meishan Road, Hefei, 230032, Anhui, China. zhanhq@ahmu.edu.cn.
Förderung
- the Graduate Research and Practice Innovation Project of Anhui Medical University
- the National Natural Science Foundation of China
- the Research Fund of Anhui Institute of Translational Medicine
Zitieren
APA
Ni, H. Y., Zhang, X. X., Wang, X. R., Ma, J., Yu, X. J., & Zhan, H. Q. (2026). TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression. Medical Oncology. https://doi.org/10.1007/s12032-026-03411-6
Vancouver
Ni HY, Zhang XX, Wang XR, Ma J, Yu XJ, Zhan HQ. TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression. Medical Oncology. 2026. doi:10.1007/s12032-026-03411-6
BibTeX
@article{Ni2026,
author = {Ni, Hai-Yan and Zhang, Xiao-Xun and Wang, Xin-Ran and Ma, Jing and Yu, Xiao-Jing and Zhan, He-Qin},
title = {TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03411-6}
}
EUVIMED